

#17 whattab.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:	)	Group Art Unit: 1648	RECEIVED
LANGRIDGE, William H.R. et al.	)	Examiner: HILL, Myron G.	MAY 01 2003
Serial No. 09/771,536	)		•
Filing Date: January 29, 2001	)		TECH CENTER 1600/2900
For: Transgenic Plant-Based Vaccines	)	Pasadena, California	

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

Dear Sir:

Attached hereto is a PTO-1449 form listing documents believed relevant to the subject application. It is respectfully requested that these documents be considered by the Examiner and an initialed copy of the form be returned to the undersigned. It should be noted the word "prior" has been deleted from the form.

It is believed this disclosure complies with the requirements of 37 C.F.R. 1.56 and the Manual of Patent Examining Procedures Section 707.05(b). If for some reason the Examiner considers otherwise, it is respectfully requested the undersigned be called so any deficiencies can be remedied.

A copy of each document is enclosed. Some of the documents may have markings thereon. No significance is meant to be attached to the markings. These documents are not necessarily analogous art.

09/771,536

The undersigned certifies under 37 CFR § 1.97(e)(1) that each of the documents listed in the attached PTO-1449 Form was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Disclosure Statement. It is believed, therefore, that no fee is due. If this is incorrect, please charge any necessary fee for consideration of this Disclosure Statement to Deposit Account No. 19-2090.

Respectfully submitted,

SHELDON & MAK a Professional Corporation

Date: April 24, 2003

David A. Farah, M.D.

Reg. No. 38,134

## **Direct all Communications to:**

David A. Farah, M.D. SHELDON & MAK PC 225 South Lake Avenue, 9th Floor Pasadena, California 91101

Tel.: (626) 796-4000 Fax: (626) 795-6321

E-mail: davidf@usip.com

### **CERTIFICATE OF MAILING**

I hereby certify that the above-identified correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202 on: April 24, 2003.

By: Marilyn Paik

# EXEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING \*INFORMATION DISCLOSURE STATEMENT

Docket No. 12273-3

Eation Of: LANGRIDGE, William H.R. et al. C& TRADE

Serial No.

Filing Date

Examiner

Group Art Unit

09/771,536

January 29, 2001

HILL, Myron G.

Invention:

TRANSGENIC PLANT-BASED VACCINES

MAY 01 2003

**TECH CENTER 1600/2900** 

## TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

# Statement Under 37 CFR 1.97(e)(1)

Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

## Statement Under 37 CFR 1.97(e)(2)

□ No item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.

Dated: April 24, 2003

David A. Farah, M.D. Reg. No. 38,134

SHELDON & MAK PC 225 South Lake Avenue, 9th Floor Pasadena, California 91101

Tel.: (626) 796-4000 Fax: (626) 795-6321

cc: L ma Linda University

I certify that this document is being deposited on

04/24/2003

with the U.S. Postal Service as first

class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C.

20231.

Signature of Person Mailing Correspondence

Marilyn Paik

Typed or Printed Name of Person Mailing Correspondence